DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Disease Level Insights

Formerly known as Decision Resources, our Disease Level Insights portfolio provides the baseline for market intelligence. In addition, our solutions provide even deeper expert-level insights into forecasting, market sizing, and gold-standard epidemiology that are required to confidently inform commercialization decisions.

Watch the video below for an introduction to our new Insights Platform – built to answer your key business questions with the latest market-relevant data for companies, drugs and diseases.

Expert-level insight into forecasting, market sizing, and gold-standard epidemiology

Expert-level Disease Level Insights

a map and globe

Landscape & Forecast

Evaluating analysis and forecasts of the commercial outlook for disease-specific drugs currently on the market, and those in research and development, including disease origins and current treatment journey by geography.

  • What are the key factors that shape the current, and will drive the future, market?
  • What is the current and future market size (in $)?
  • Who are the players and providers of care?
Talk to us 

Pharmacor, Emerging Markets, China Rx, Rare and Niche Diseases


Sizing market potential with gold-standard epidemiology.

  • How big is the total potential market (prevalent/incident patients) ? and total addressable market (diagnosed/targeted sub-population)?
  • What is the potential commercial value of a product (using a ‘bottom-up’ build)?
  • How will these populations change over time?
Learn more


hand with a pen writing

Current Treatment

Exploring patient-level data to understand physician’s attitudes, perceptions, and self-reported prescribing behavior and uncover the ‘why’ behind treatment decisions while using claims-level data to quantify lines of therapy.

  • What patients are being prescribed which drugs?
  • What are the clinical and physician-reported determinants for current prescribing patterns and trends over time?
  • What is the source of business for a drug (new starts, adding/switching patterns), with trends over time?
Talk to us 

TreatmentTrends, ChartTrends

3-D arrows twirling upward

Unmet Need

Analyzing crucial unmet needs and identifying opportunities in drug development.

  • What are the most important clinical unmet needs (endpoints) to physicians?
  • How are emerging therapies poised to shape treatment and where will need remain?
  • What is the corresponding commercial opportunity?
Talk to us 


upclose blurry view colorful pill capsules

Emerging Therapies

Studying uptake and impact of new products on market dynamics.

  • How aware are physicians of a drug at launch and during its first year?
  • What are physicians’ perceptions of the product/willingness to prescribe?
  • How has the new drug impacted its immediate competitive environs?
Talk to us 


Access & Reimbursement

Examining brand-specific market access insights built on primary physician and payer research.

  • What are the key market access levers and barriers for current and emerging brands in specific markets?
  • Who are the key reimbursement decision makers and what criteria will they use?
  • How can messaging to clinicians and payers be optimized?
Talk to us 

Physician & Payer Forum

Our latest thoughts and commentary


Latest articles

JAK inhibitors in IBD

On the Way to Becoming JAKs of All Trades On July 13th, 2017 Pfizer announced that its application for approval in ulcerative...

More Articles

In the news
News articles citing DRG analysts data.
More News